First Sanofi lowered the price of Lantus and now Novo Nordisk is lowering the price on one of its best-selling diabetes products – the long-acting basal insulin, Levemir.
It has yet to be finally decided what reimbursements for the individual diabetes drugs will look like, but the Danish Reimbursement Committee offers its advice, which is then released for consultation.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app